ClinicalTrials.gg
TerminatedNCT04806152Updated Mar 19, 2021

Sarcopenia and Combined-modality Exercise

An interventional study of High intensity exercise and Usual care home exercise in Sarcopenia, sponsored by The University of The West Indies. Terminated at 1 site in Jamaica. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by The University of The West Indies · Not applicable, Interventional, and Treatment

Why this study was terminated
The COVID19 outbreak began March 2020 in Jamaica. Associated risks, prohibitive cost of mitigating those risks for study participants and locally enacted legislation militated against further recruitment and intervention activities.

From the registry’s dates

  • Registered 3 years 10 months after the study started (first participant enrolled May 2017, registered Mar 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Study summary

This study examined the effects of combined-modality exercise training (resistance, endurance, flexibility and balance) on muscle mass, muscle function and physical activity in community-dwelling elderly living in Jamaica who had been characterised as having sarcopenia.

Read the detailed description

Community-dwelling seniors aged 60 years and older were screened for muscle mass and function (grip strength and walk speed) and persons with sarcopenia were identified using the European Working Group on Sarcopenia in Older Persons (EWGSOP) algorithm for case finding (N=1344). Of the 77 seniors with sarcopenia, 38 consented to participate and were randomly allocated to receive 6 months combined-modality high intensity treadmill based exercise and a 'usual care' home exercise programme. A comparison of the effects of treatment assignment on muscle mass, function, fitness, physical activity level and disability was done. Participants in the supervised combined-modality high intensity group were required to attend sessions 3 times per week; participants in the home exercise programme were required to attend 1 supervised session at the start of their 6-month intervention. Outcomes were assessed at baseline and at the end of the 6-month intervention. Data were analysed using standard statistical parametric and non-parametric methods including repeated measures analysis of variance to determine changes in outcomes and regression to establish determinants of outcomes.

02

Conditions studied

  • Sarcopenia

Keywords

  • exercise
  • training
03

In context

Sarcopenia

1,329 studies on the registry are indexed under Sarcopenia; 420 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 855 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

The University of The West Indies is the lead sponsor of 64 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • over 60 years old,
  • independently ambulant, with or without an assistive device
  • mentally competent to give and follow exercise instructions

Exclusion criteria

Exclusion Criteria:

  • a history of stroke with residual disability
  • a diagnosis of cancer
  • neuromuscular disorders
  • auto-immune disorders
  • dementia
  • severe arthritis rendering participation in an exercise programme difficult
  • unstable cardiovascular disease which renders exercise unsafe
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Sarcopenia and combined-modality high intensity supervised exercise training

    Participants were given Treadmill exercise training, lower extremity progressive resistance training using a Cybex leg press machine, and a 1-hour adaptive physical activity (APA) programme in which participants were required to walk for 12 minutes through an obstacle course in which they must clear 10 cm high boards, climb 3 steps and walk sideways through hula-hoops placed on the floor all the while dual-tasking i.e. waving at strategically placed signs, conversing while walking and picking up objects. Participants also performed exercises at the parallel bars which included weight-shifting from leg to leg and half-squatting; they were also guided through seated upper- and lower-limb stretching exercises for range of motion and trunk mobility. All exercise sessions were supervised by physiotherapists. For two of the weekdays on which participants did not attend supervised training, they were asked to walk for 30 minutes at home and perform the APA exercises described above.

    Other: High intensity exercise

  • Active comparator
    Sarcopenia and 'usual care' unsupervised exercise

    Participants were required to do 5-12 chair rises and also 30-minutes walking 5 days per week. Upper limb and trunk flexibility exercises were also taught.

    Other: Usual care home exercise

Interventions

  • OtherHigh intensity exercise

    Supervised high-intensity combined-modality exercise was administered to participants in the exercise arm for 3 times per week for 6 months. A post-exercise recovery protein drink (31g whey-based) was given within 15 minutes after each supervised exercise session.

  • OtherUsual care home exercise

    Walking 30 minutes, chair rises and flexibility exercises for trunk and upper extremities 5 days per week

06

What researchers measure

Primary outcomes

  1. Functional endurance

    Distance walked in 6 minutes

    Time frame: 6 months

  2. Disability

    Lawton Instrumental Activities of Daily Living scale: minimum score = 0 (low function, dependent); maximum score = 8 (high function, independent). Lower scores indicate a worse outcome.

    Time frame: 6 months

  3. Lower extremity (LE) functional strength

    1-repetition maximum (RM) strength

    Time frame: 6 months

  4. Accelerometry

    weekly energy expenditure

    Time frame: 6 months

  5. self-selected walk speed

    speed in the timed-10-metre walk

    Time frame: 6 months

  6. Appendicular lean mass index

    dual energy x-ray absorptiometry (DEXA) measured appendicular lean mass summed and divided by height squared, expressed in kg/m2

    Time frame: 6 months

  7. Balance

    Berg balance test score: minimum score = 0, maximum score = 56. Lower values indicate worse outcome

    Time frame: 6 months

  8. Fat-free mass

    dual energy x-ray absorptiometry (DEXA) determined: fat mass subtracted from weight, expressed in kg

    Time frame: 6 months

Secondary outcomes

  1. Depression

    Center for Epidemiological Studies-Depression \[CES-D\] score: minimum score = 0, maximum score = 60, with higher scores indicating more depressive symptoms

    Time frame: 6 months

  2. Timed-up-and-go

    Functional test indicating fall risk

    Time frame: 6 months

07

Study locations

1 site
  • UWI Solutions for Developing Countries (SODECO)
    Kingston 7, KSA JMAKN04, Jamaica
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2017 to primary completion in Mar 2020, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2021
First posted
Mar 19, 2021
StartActual
May 2, 2017
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Last update
Mar 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04806152
Lead sponsor
The University of The West Indies
Responsible party
Sponsor
First posted
Mar 19, 2021
Start date
May 2, 2017
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Last update
Mar 19, 2021

Study contacts

Terrence Forrester, PhD
principal investigator · UWI Solutions for Developing Countries
Michael Boyne, MD
principal investigator · UWI Department of Medicine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion